Skip to Main Content

Author Details

Stacie B Dusetzina
Vanderbilt University School of Medicine, TN Vanderbilt Ingram Cancer Center
2009
242
33
PMIDPaper TitleJournal TitlePublished Year
37983024Medicare Part D Payments for Generic Imatinib From 2017 to 2023.JAMA Intern Med2024
37778479Analyzing Access and Costs of Oral Medications for Overactive Bladder: Uncovering Disparities.Urology2024
35918053Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures.Int J Radiat Oncol Biol Phys2023
38086014Designing a Digital Tool to Inform Oncology Practices About Cancer Treatment Cost Burdens.JCO Clin Cancer Inform2023
37669068Cost-Related Barriers and Ensuring Equitable Access to Vaccines in the US.JAMA Pediatr2023
37963035Avenues for Strengthening PCORnet's Capacity to Advance Patient-Centered Economic Outcomes in Patient-Centered Outcomes Research (PCOR).Med Care2023
37548972Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder.JAMA Intern Med2023
37738532Health Care Contact Days Experienced by Decedents With Advanced GI Cancer.JCO Oncol Pract2023
37982509The Association Between Solid Organ Transplant and Recurrence of Acute Diverticulitis: A National Assessment.Ann Surg2023
37879723Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study.BMJ2023
37725598Trends in U.S. self-reported health and self-care behaviors during the COVID-19 pandemic.PLoS One2023
35808853Demand for and Occurrence of Medication Cost Conversations: A Narrative Review.Med Care Res Rev2023
35697969Gender-Affirming Hormone Therapy Spending and Use in the USA, 2013-2019.J Gen Intern Med2023
37252717Health Insurer Strategies to Reduce Specialty Drug Spending-Copayment Adjustment and Alternative Funding Programs.JAMA Intern Med2023
37416955Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment.J Urol2023
37213097Time to Confirmatory Study Initiation After Accelerated Approval of Cancer and Noncancer Drugs in the US.JAMA Intern Med2023
37409930Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer.Urol Pract2023
37341420The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer.J Urol2023
37229783Association between low-income subsidies and inequities in orally administered antimyeloma therapy use.Am J Manag Care2023
37200029Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022.JAMA Netw Open2023
37097432The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?Curr Cardiol Rep2023
37477929Trends in the Use of Mifepristone for Medical Management of Early Pregnancy Loss From 2016 to 2020.JAMA2023
37067794Examining Opportunities to Increase Savings From Medicare Price Negotiations.JAMA Intern Med2023
37329296High Deductible Health Plans and Use of Free Preventive Services Under the Affordable Care Act.Inquiry2023
37029039Financial toxicity of oral therapies in advanced prostate cancer.Urol Oncol2023
37462712Utilization Management Trends in Medicare Part D Oncology Drugs, 2010-2020.JAMA2023
37428489Commercial Health Plan and Enrollee Out-of-Pocket Spending on Accelerated Approval Products in 2019.JAMA Intern Med2023
37428191Medicare's Plan for Drug-Price Negotiation - The Importance of Defining Generic Entry.N Engl J Med2023
36912541Medicare Part D Coverage of Antiobesity Medications - Challenges and Uncertainty Ahead.N Engl J Med2023
36637794"Worth it if you could afford it": Patient perspectives on integrating real-time benefit tools into drug cost conversations.J Am Geriatr Soc2023
36534375Stemming Medicare Spending on Discarded Drugs-Waste Not, Want Not?JAMA Intern Med2023
36630145Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act.JAMA Cardiol2023
36229377Out-of-pocket costs of oral anticancer drugs for Medicare beneficiaries vary by strength and formulation.J Geriatr Oncol2023
34027607Extra Help Needs a Hand: Partial Subsidies in the Medicare Part D Program.J Gen Intern Med2022
35507526Your Money or Your Life - The High Cost of Cancer Drugs under Medicare Part D.N Engl J Med2022
35377748Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions.Health Aff (Millwood)2022
35435948Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance.JAMA Intern Med2022
35671056Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.JAMA Netw Open2022
35793197Accelerated Approval - Taking the FDA's Concerns Seriously.N Engl J Med2022
35763285Intermediate Strengths and Inflated Prices: The Story of Transdermal Fentanyl Patches.J Palliat Med2022
35788377Communicating Research to Non-Researcher Audiences: A Panel Discussion From the National Cancer Institute's Future of Cancer Health Economics Research Conference.J Natl Cancer Inst Monogr2022
35816318Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020.JAMA Netw Open2022
35623024Finding the Lowest-Cost Pharmacy for Cancer Supportive Care Medications: Not So Easy.JCO Oncol Pract2022
36580324Cost-Sharing Reform for Chronic Disease Treatments as a Strategy to Improve Health Care Equity and Value in the US.JAMA Health Forum2022
36399351Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs.JAMA Health Forum2022
36512134The least costly pharmacy for cancer supportive care medications over time: the logistic toxicity of playing catch up.Support Care Cancer2022
36178694Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products.JAMA Netw Open2022
36107430Monthly Cost-Sharing Limits and Out-of-pocket Costs for Commercially Insured Patients in the US.JAMA Netw Open2022
35867554The Price of Progress: Managing Prescription Drug Spending.J Health Polit Policy Law2022
35867545Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits.J Health Polit Policy Law2022
  • 1 - 50 of 242

Recommended Authors

Michelle S Keller
Cedars-Sinai Medical Center
Career Start Year 2017
Number of shared co-authors 0
Eric Barrette
Health Care Cost Institute
Career Start Year 2016
Number of shared co-authors 1
Hemalkumar B Mehta
Johns Hopkins Bloomberg School of Public Health
Career Start Year 2012
Number of shared co-authors 3
John N Mafi
University of California Los Angeles, California and RAND Corporation
Career Start Year 2011
Number of shared co-authors 0
Pamala A Pawloski
HealthPartners Institute
Career Start Year 2011
Number of shared co-authors 0
Suja S Rajan
UTHealth School of Public Health
Career Start Year 2008
Number of shared co-authors 0
Sanket S Dhruva
University of California san francisco
Career Start Year 2008
Number of shared co-authors 4
Seth A Seabury
USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Career Start Year 2005
Number of shared co-authors 0
Joshua J Gagne
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital
Career Start Year 2005
Number of shared co-authors 3
Christine Y Lu
Harvard Medical School and the Harvard Pilgrim Health Care Institute
Career Start Year 2004
Number of shared co-authors 0
James M Hoffman
St. Jude Children's Research Hospital Memphis
Career Start Year 2003
Number of shared co-authors 3
June M McKoy
Feinberg School of Medicine, Northwestern University
Career Start Year 2003
Number of shared co-authors 1
Michele Jonsson Funk
University of North Carolina at Chapel Hill
Career Start Year 2002
Number of shared co-authors 2
Jalpa A Doshi
University of Pennsylvania Perelman School of Medicine
Career Start Year 2002
Number of shared co-authors 0
Kavita Patel
Brookings Institution - USC Schaeffer Initiative on Health Policy.
Career Start Year 2001
Number of shared co-authors 0
Mary Kate Bundorf
Duke University
Career Start Year 1999
Number of shared co-authors 0
John Hsu
Mongan Institute, Massachusetts General Hospital and Harvard Medical School
Career Start Year 1999
Number of shared co-authors 0
Yong-Fang Kuo
University of Texas Medical Branch at Galveston
Career Start Year 1997
Number of shared co-authors 1
Trudy Millard Krause
School of Public Health, The University of Texas Health Science Center at Houston
Career Start Year 1997
Number of shared co-authors 0
Emily Beth Devine
University of Washington
Career Start Year 1997
Number of shared co-authors 0
Todd H Wagner
Stanford University School of Medicine
Career Start Year 1996
Number of shared co-authors 1
Sebastian Schneeweiss
Division of Pharmacoepidemiology, Brigham & Women's Hospital, Harvard Medical School
Career Start Year 1996
Number of shared co-authors 3
Ellen Meara
Harvard T.H. Chan School of Public Health
Career Start Year 1995
Number of shared co-authors 3
Andrew J Epstein
University of California san francisco
Career Start Year 1993
Number of shared co-authors 2
Dana P Goldman
University of Southern California
Career Start Year 1992
Number of shared co-authors 0
Chris L Pashos
Data Sciences Institute, Takeda Pharmaceuticals International Inc.
Career Start Year 1990
Number of shared co-authors 0
Robert S Epstein
Epstein Health LLC
Career Start Year 1988
Number of shared co-authors 0
Elizabeth A Chrischilles
University of Iowa, School of Public Health
Career Start Year 1982
Number of shared co-authors 1
Dennis W Raisch
The University of New Mexico
Career Start Year 1977
Number of shared co-authors 1
Stan N Finkelstein
University of Toronto
Career Start Year 1977
Number of shared co-authors 0

Collaborators

Til St??rmer
University of North Carolina at Chapel Hill
Co-authored papers 13
Stephanie B Wheeler
Co-authored papers 9
George Caleb Alexander
Institute of General Practice and Family Medicine, University Hospital
Co-authored papers 7
Lydia E Pace
Brigham and Women's Hospital
Co-authored papers 5
Lisa A Carey
Co-authored papers 4
Michelle M Mello
Co-authored papers 4
Alistair J O'Malley
The Dartmouth Institute, Geisel School of Medicine at Dartmouth
Co-authored papers 3
Susan L Mitchell
Hebrew SeniorLife Hinda and Arthur Marcus Institute for Aging Research (S.S.
Co-authored papers 3
Anna D Sinaiko
Harvard T.H. Chan School of Public Health, Harvard University
Co-authored papers 3
Hazel B Nichols
Co-authored papers 2
Russell L Rothman
Vanderbilt University School of Medicine
Co-authored papers 2
Nilay D Shah
Mayo Clinic
Co-authored papers 2
Aaron S Kesselheim
Brigham and Women's Hospital.
Co-authored papers 2
Melissa A Troester
Co-authored papers 2
Todd A Durham
Foundation Fighting Blindness
Co-authored papers 1
Laura M Keohane
Vanderbilt University School of Medicine
Co-authored papers 1
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 1
Phillip J Schulte
Division of Clinical Trials and Biostatistics, Mayo Clinic
Co-authored papers 1
Joseph S Ross
Yale School of Medicine
Co-authored papers 1
Fred Saad
University of Montreal Health Center
Co-authored papers 1
Deepak Voora
Durham VA Healthcare System and Duke University
Co-authored papers 1
Emily W Gower
University of North Carolina at Chapel Hill
Co-authored papers 1
Patrick Yachimski
Co-authored papers 1
Rohan Khera
Yale School of Medicine
Co-authored papers 1
Dietger Niederwieser
University of Leipzig
Co-authored papers 1
Jessica A Lavery
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Colin G Walsh
Vanderbilt University, Vanderbilt University Medical Center
Co-authored papers 1
Mark E Frisse
Vanderbilt University Medical Center
Co-authored papers 1
Michael Anne Kyle
Harvard Medical School and Dana Farber Cancer Institute
Co-authored papers 1
Charles B Eaton
Co-authored papers 1
Release 1.2